ReviewCurrent issues in molecular biology2026
Irisin in Cardiovascular Health and Disease: A Review of Its Function as a Biomarker and Therapeutic Target in Atherosclerosis and Related Conditions.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality worldwide, necessitating novel biomarkers and therapeutic targets. Irisin, a myokine derived from FNDC5, has emerged as a molecule of interest owing to its pleiotropic effects, yet its role in cardiovascular health is debated amid conflicting clinical findings and severe measurement challenges. This review synthesizes and critically evaluates the evidence on irisin in ASCVD, examining its molecular mechanisms, potential as a clinical biomarker, and hurdles for therapeutic application. Preclinical evidence has demonstrated that irisin exerts multifaceted cardioprotective effects: it mitigates cellular stress by enhancing mitochondrial quality control and inhibiting apoptosis and pyroptosis; preserves vascular integrity by promoting angiogenesis and preventing pathological remodeling; and enhances the efficacy of regenerative stem cell therapies. Most clinical studies have revealed an inverse correlation between circulating irisin levels and the presence and severity of ASCVD, heart failure, and related inflammatory conditions. However, these studies are predominantly observational and often cross-sectional, frequently with small sample sizes, and paradoxical elevations occur in certain metabolic states and during acute cardiac injury. Critically, the field is hampered by profound measurement inconsistencies, with reported values spanning picograms to micrograms per millilitre, making cross-study comparisons and clinical cutoffs currently impossible. Irisin appears to be an important endogenous factor in cardiovascular health, and preclinical evidence suggests that it is a promising candidate therapeutic target; however, clinical validation is lacking. Standardization of irisin assays remains the critical step required to determine whether irisin can become a reliable clinical biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.